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OBJECTIVE—The “portal hypothesis” proposes that the liver is
directly exposed to free fatty acids and cytokines increasingly
released from visceral fat tissue into the portal vein of obese
subjects, thus rendering visceral fat accumulation particularly
hazardous for the development of hepatic insulin resistance and
type 2 diabetes. In the present study, we used a fat transplanta-
tion paradigm to (artiﬁcially) increase intra-abdominal fat mass
to test the hypothesis that venous drainage of fat tissue deter-
mines its impact on glucose homeostasis.
RESEARCH DESIGN AND METHODS—Epididymal fat pads
of C57Bl6/J donor mice were transplanted into littermates, either
to the parietal peritoneum (caval/systemic venous drainage) or,
by using a novel approach, to the mesenterium, which confers
portal venous drainage.
RESULTS—Only mice receiving the portal drained fat trans-
plant developed impaired glucose tolerance and hepatic insulin
resistance. mRNA expression of proinﬂammatory cytokines was
increased in both portally and systemically transplanted fat pads.
However, portal vein (but not systemic) plasma levels of inter-
leukin (IL)-6 were elevated only in mice receiving a portal fat
transplant. Intriguingly, mice receiving portal drained transplants
from IL-6 knockout mice showed normal glucose tolerance.
CONCLUSIONS—These results demonstrate that the metabolic
fate of intra-abdominal fat tissue transplantation is determined
by the delivery of inﬂammatory cytokines to the liver speciﬁcally
via the portal system, providing direct evidence in support of the
portal hypothesis. Diabetes 60:56–63, 2011
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everal hypotheses have been formulated and pur-
sued to explain the deteriorating impact of intra-
abdominal (visceral) adipose tissue accumulation
on glucose metabolism: intra-abdominal fat tissue
may be inherently different from subcutaneous fat, e.g., in
cellular composition, tissue dynamics (tendency to re-
spond to excess calories with a hypertrophic rather than a
hyperplastic response), adipokine release, and hormonal
responses. Alternatively (or complementarily), the venous
drainage of subcutaneous fat differs from that of visceral
fat: secreted products such as adipocytokines and free
fatty acids (FFAs) from subcutaneous fat are drained
systemically into the vena cava, whereas secreted prod-
ucts from mesenteric or visceral fat are drained into the
portal system. Exaggerated hepatic delivery of FFAs and
proinﬂammatory cytokines originating from adipose tissue
(and/or the gastrointestinal tract) result in hepatic insulin
resistance and metabolic deterioration constituting “the
portal theory” (1–4).
We previously found that increasing fat mass by intra-
abdominal transplantation of fat pads isolated from
healthy non–insulin-resistant littermates could not recapit-
ulate the effects of fat accumulation in obesity in healthy
recipient mice. Instead, increased insulin sensitivity and
improved glucose tolerance were observed (5). Yet, blood
from these fat pads is drained into the vena cava inferior
and thus reaches the systemic circulation while circum-
venting the liver. A prominent hypothesis linking visceral/
intra-abdominal adiposity to cardio-metabolic diseases
involves the tight association with fatty liver diseases,
which is explained by the portal theory. Thus, it is plausi-
ble that the metabolic effect of intra-abdominal adipose
tissue transplantation depends on the venous drainage of
the transplant. Indeed, in a recent study, no difference was
reported in glucose tolerance between mice receiving an
intra-abdominal fat transplant and sham-operated mice
(6), potentially because transplants were drained to both
the caval as well as the portal circulation.
The aim of the present study was to test the hypothesis
that venous drainage of fat tissue determines its impact on
glucose homeostasis. To this end, we developed a novel
approach to mimic visceral fat accumulation by trans-
planting fat pads from a donor mouse to the mesenterium
of a recipient littermate. These pads are drained solely to
the portal vein. In contrast to mice receiving caval drained
fat pad transplantation, mice receiving a portal drained fat
pad developed (hepatic) insulin resistance and were glu-
cose intolerant. Furthermore, we present evidence that
interleukin (IL)-6 is at least partly responsible for impaired
glucose metabolism in these mice. Thus, our results hint
toward an important inﬂuence of venous drainage of fat
pads on glucose homeostasis, supporting the portal
hypothesis.
RESEARCH DESIGN AND METHODS
Animals. Male C57BL6JOlaHsd mice were purchased from Harlan Nether-
lands (Harlan, Horst, the Netherlands), and male IL-6 KO mice and respective
wild-type mice were purchased from Charles River Laboratories (Wilmington,
MA). All mice were housed in a pathogen-free environment on a 12-h
light-dark cycle, with free access to standard rodent diet (Provimi Kliba,
Kaiseraugst, Switzerland). All protocols conformed to the Swiss animal
protection laws and were approved by the Cantonal Veterinary Ofﬁce in
Zurich, Switzerland.
Surgical procedure. Transplantation procedure was performed at 6 weeks of
age. Mice were anesthetized with isoﬂurane (Abbott, Baar, Switzerland). Both
epididymal fat pads (average size per pad 75 mg [range 65–90 mg]) were
removed from the donor mouse, rinsed with 0.9% saline, and thereafter
stitched to the visceral side of the peritoneum (caval transplantation) or to the
mesenterium of the recipient mouse (portal transplantation) using Monocryl
6.0 (Johnson-Johnson, Spreitenbach, Switzerland). Sham-operated control
mice underwent the same surgical procedure without receiving a fat trans-
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56 DIABETES, VOL. 60, JANUARY 2011 diabetes.diabetesjournals.orgplant. Subcutaneous injection of buprenorphine every 12 h for 2 days was used
for analgesia. To prevent transplant rejection, donor and recipient mice were
littermates.
Glucose tolerance tests. For the intraperitoneal glucose tolerance test, mice
were fasted overnight. Glucose (2 g/kg body wt) was injected intraperitoneally
and blood was collected from the tail vein at different time points, as indicated
(5). Plasma glucose was measured using a glucose meter (Ascensia Contour;
Bayer, Zurich, Switzerland).
Histology. Fat tissues were ﬁxed in 4% buffered formalin and embedded in
parafﬁn. Sections were obtained at the time of death and stained with
hematoxylin and eosin. For each fat pad of a mouse, at least 100 adipocytes
were analyzed. Images were analyzed using ImageJ software for quantiﬁ-
cation (National Institutes of Health, Bethesda, MD). Macrophages were
immunostained with mac2 antibody. Mac2-positive cells were counted per
nuclei of seven randomly selected ﬁelds per section containing at least 90
cells.
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FIG. 1. Transplantation was performed at 6 weeks of age. Both
epididymal fat pads were removed from a donor mouse and
stitched to the mesenterium (pTx) of a littermate recipient. A:
Six weeks after transplantation, the abdominal cavity was
opened and the transplanted fat pad was visualized. B:T o
conﬁrm portal drainage of transplanted fat pads, Evans blue dye
(5 mg/ml) was injected into the portal vein. Arrow: portal
transplanted fat pad. C: Intraperitoneal glucose tolerance test (2
g glucose/kg body weight) was performed 4 weeks after surgical
procedure in mice receiving portal drained transplants (pTx; E),
in mice receiving caval drained transplants (cTx; ), or in
sham-operated mice (F) after an overnight fast. Results are
expressed as mean blood glucose concentration (left panel)o r
area under curve (AUC) (right panel)  SEM of 5 (pTx), 16 (cTx), or 23 (sham) animals. **P < 0.01, #P < 0.001 (left panel: Student t test [pTx
vs. sham]; right panel: ANOVA). D: Both epididymal fat pads were removed from a donor mouse. One was stitched to the peritoneum (caval
drained; cTx) and the other to the mesenterium (portal drained; pTx) of a littermate. Intraperitoneal glucose tolerance test (2 g glucose/kg body
wt) was performed 4 weeks after surgical procedure in mice receiving a double transplant (cTx  pTx; ‚) or in sham-operated mice (F) after an
overnight fast. Results are expressed as mean blood glucose concentration  SEM of three to eight animals. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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moving mice 5 weeks after transplantation as described previously (7).
Glucose infusion rate was calculated once glucose infusion reached a more or
less constant rate with blood glucose levels at 5 mmol/l. This was reached in
most mice 80–90 min after the start of insulin infusion. Thereafter, blood
glucose was kept constant at 5 mmol/l for 20 min (with no or minimal
adjustment of the glucose infusion rate), and glucose infusion rate was
calculated. The glucose disposal rate was calculated by dividing the rate of
[3-
3H]glucose infusion by the plasma [3-
3H]glucose speciﬁc activity (8,9).
Endogenous glucose production during the clamp was calculated by subtract-
ing the glucose infusion rate from the glucose disposal rate (8,9). Insulin-
stimulated glucose disposal rate was calculated by subtracting basal
endogenous glucose production (equal to basal glucose disposal rate) from
glucose disposal rate during the clamp (10).
Determination of plasma adiponectin, leptin, IL-6, insulin, and FFA.
Plasma adiponectin, leptin, and IL-6 levels were determined with mouse
LINCOplex kits from Linco Research (Labodia, Yens, Switzerland); plasma
insulin and FFA levels were measured as previously described (5).
Total liver lipid extraction. Liver tissue (30 mg) was homogenized in PBS,
and lipids were extracted in a chloroform-methanol (2:1) mixture. Total liver
lipids were determined by a sulfophosphovanillin reaction as previously
described (7).
RNA extraction and quantitative RT-PCR. Total RNA from fat pads was
extracted with the RNeasy lipid tissue mini-kit (Qiagen). A total of 0.75 g
RNA was reverse-transcribed with Superscript III Reverse Transcriptase
(Invitrogen) using random hexamer primer (Invitrogen). Taqman system
(Applied Biosystems) was used for real-time PCR ampliﬁcation. Relative
gene expression was obtained after normalization to 18sRNA (Applied
Biosystems), using the formula 2
cp (11). The following primers were
used: TNF- Mm004483258_m1, IL-6 Mm00446190_m1, KC Mm00433859_m1,
IL-1 Mm0043422/_m1, MCP-1 Mm00441242_m1, Fas Mm00433237_m1, FasL
Mm00438864_m1, cd11c Mm00498698_m1, Hif-1 Mm00468869_m1, SOCS.3
Mm 00545913_s1, CD68 Mm03047343_m1, F4/80 Mm00802529_m1, and
cd11b Mm00434455_m1 (Applied Biosystems).
Western blot. Western blotting was performed as previously described (7).
The following antibodies were used: anti–phospho-Akt (S473) and anti-Akt
were purchased from Cell Signaling; secondary horseradish peroxidase–
conjugated antibody were purchased from either Santa Cruz Biotechnology or
Alexis Biochemicals.
Data analysis. Data are presented as means  SEM and were analyzed by
Student t test or ANOVA with a Turkey correction for multiple group
comparisons.
RESULTS
To estimate potential metabolic effects of an artiﬁcial
increase in fat tissue mass drained uniquely into the portal
system, epididymal fat pads of a regular diet–fed donor
mouse were transplanted to the mesenterium of a regular
diet–fed littermate mouse using a novel surgical approach.
At the time of death (5 weeks after transplantation),
transplanted fat pads were adherent to the mesenterium
and well vascularized (Fig. 1A). Sham operation was
performed in control littermates. Mice tolerated the surgi-
cal procedure and the fat transplantation well; no adverse
events were noted. To conﬁrm venous drainage of trans-
planted fat pads to the portal vein, Evans Blue was
injected retrogradely into the portal vein. As depicted in
Fig. 1B, transplanted fat pads were stained with Evans
Blue, as was endogenous mesenteric fat tissue, but not the
caval-drained epididymal fat tissue, conﬁrming the portal
drainage of the mesenteric-transplanted fat tissue.
We have previously shown that mice receiving fat pads
drained to the inferior vena cava (caval-drained fat trans-
plantation [cTx]) had improved glucose tolerance (5).
Four weeks after transplantation, body weight gain was
not different between sham-operated mice and mice re-
ceiving a portal-drained fat transplant (3.0  0.4 vs. 2.9 
0.5 g; P  0.85). However, as depicted in Fig. 1C, increase
in blood glucose concentrations after an intraperitoneal
glucose load was signiﬁcantly higher in mice receiving a
fat transplant drained to the portal vein (portal-drained fat
pad transplantation [pTx]) compared with mice receiving
cTx, as well as to sham-operated mice, indicating impaired
glucose tolerance in mice receiving a pTx.
To determine whether the effect on glucose homeostasis
of one transplantation site predominates over the other, a
double transplantation approach was performed, i.e., one
epididymal fat pad of the donor mouse was stitched to the
epididymal mesenteric portal Tx
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FIG. 2. A: Representative hematoxylin- and eosin-stained histological
sections of endogenous epididymal, endogenous mesenteric, or portal-
transplanted fat pads from sham-operated and pTx mice are shown 5
weeks after surgery. Adipocyte cell perimeter was measured using
ImageJ. B: Up to 100 cells for each fat pad were analyzed, and the
results represent the mean  SEM of three or four different mice. Black
bar: sham-operated mice; white bar: mice receiving a portal fat trans-
plant. C: Histological sections of endogenous epididymal and portal-
transplanted tissue were immunostained with mac2 antibody. Mac2-
positive cells were counted in seven randomly selected ﬁelds per
section (about 90 cells) and expressed relative to total cell nucleus
content. Results represent the mean  SEM of three to ﬁve different
mice. All values are expressed relative to Mac2-positive cells of epidi-
dymal fat pad of sham-operated mice.
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and the other pad was stitched to the mesenterium (and
thus drained to the portal vein). Transplanted fat pads
were similar in size and originated from the same donor
mouse, which was a littermate of the recipient mouse. As
depicted in Fig. 1D, glucose tolerance in such transplanted
mice was not different from sham-operated mice 4 weeks
after surgery.
We next assessed adipose tissue morphology of endog-
enous and transplanted fat pads in sham-operated and pTx
mice (Fig. 2A). As depicted in Fig. 2B, perimeters of
endogenous epididymal and mesenteric adipocytes were
similar in both groups. However, epididymal adipocytes
were larger than mesenteric adipocytes. Moreover, adipo-
cytes in portal-transplanted fat pads were similar in size as
endogenous mesenteric adipocytes but smaller than en-
dogenous epididymal adipocytes. Furthermore, macro-
phage inﬁltration rate was much higher in portal-
transplanted fat pads than endogenous epididymal fat
pads of transplanted and sham-operated mice (Fig. 2C).
Consistent with the portal theory, we hypothesized that
portal drainage of fat transplant would cause hepatic
insulin resistance, and to assess this possibility, a hyper-
insulinemic-euglycemic clamp was performed 5 weeks
after surgery. Glucose infusion rate was signiﬁcantly lower
in portal-transplanted mice than in sham-operated mice
(Fig. 3A and supplementary Figure S1 [available in an
online appendix at http://diabetes.diabetesjournals.org/
cgi/content/full/db10-0697/DC1). Moreover, during a hyper-
insulinemic-euglycemic clamp, insulin-induced suppression
of endogenous glucose production was blunted in mice
receiving a fat pad transplant drained to the portal vein, but
was clearly evident in sham-operated mice (Fig. 3B, left
panel). Therefore, mice receiving portal drained fat pad
transplants developed hepatic insulin resistance. Further-
more, insulin-induced phosphorylation of Akt was markedly
reduced in livers of portal-transplanted mice compared with
that of sham-operated mice (Fig. 3C,left panel). This eminent
reduction in hepatic insulin signaling conﬁrmed the develop-
ment of hepatic insulin resistance in portal-transplanted
mice. In contrast, glucose disposal rate (Fig. 3B, right panel)
as well as insulin signaling in skeletal muscle were not
affected by the portal-drained transplant (Fig. 3C, right
panel), suggesting maintained insulin sensitivity of skeletal
muscle. Intriguingly, insulin levels (3 h after food with-
drawal) were only slightly increased in systemic samples but
clearly elevated in portal blood samples of mice receiving a
portal fat transplantation compared with sham-operated
mice (Fig. 3D), matching the clamp results presented above.
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FIG. 3. A and B: Hyperinsulinemic-euglycemic clamps were performed 5 weeks after trans-
plantation. A: Mean glucose infusion rate (see RESEARCH DESIGN AND METHODS). B: Endogenous
glucose production (EGP; left panel) as well as insulin-stimulated glucose disposal rate
(IS-GDR; right panel) were calculated in the basal period and in response to insulin infusion
(18 mU/kg*min) during the clamp study. Results are the mean  SEM of ﬁve to six animals.
*P < 0.05 (Student t test). C: Insulin (1 U/kg) was injected intraperitoneally in overnight
fasted mice 5 weeks after transplantation. Liver and skeletal muscle samples were harvested
15 min later, and phosphorylation of Akt at S473 was determined by Western blotting. A
representative blot is shown in the upper panel. Results are the mean  SEM of three to four
animals. **P < 0.01 (Student t test). D: Blood samples were obtained as indicated, and insulin
was determined as described in RESEARCH DESIGN AND METHODS. Results are expressed as mean
plasma insulin concentration  SEM of ﬁve to six animals.
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tal-transplanted mice are presented in Table 1.
The development of hepatic insulin resistance is often
associated with hepatic steatosis and Kupffer cell activa-
tion (12). Thus, hepatic lipid contents as well as expres-
sion levels of tissue macrophage markers were assessed.
Histological examinations and biochemical determination
of total hepatic lipid content was similar in sham-operated
and peritoneal-transplanted mice (Fig. 4A). Moreover, no
increased inﬁltration/activation of hepatic Kupffer cells
was detected (Fig. 4B). Consistent with the absence of
hepatic steatosis in portal-transplanted mice, no differ-
ences in systemic and portal plasma FFA levels were
found in both groups of mice (Fig. 4C). Similarly, no
difference in circulating adiponectin and leptin levels
occurred (Table 1.). Thus, transplantation of fat pads to
sites drained by the portal vein induces hepatic insulin
resistance independently of hepatic steatosis and Kupffer
cell inﬁltration/activation.
We next sought to investigate potential mediators of
hepatic insulin resistance observed in mice receiving a
pTx. Transplanted fat tissue may not acquire the exact
biological function as the endogenous fat tissue of the
same depot, and its function may be affected by a combi-
nation of host and donor factors. Thus, to determine
potential differences between caval- and portal-trans-
planted fat pads, we used endogenous and transplanted fat
depots from the double-transplanted mice. Such an ap-
proach allowed us to exclude different host factors, as well
as secondary metabolic effects induced by cTx versus pTx,
as shown in Fig. 1. As depicted in Fig. 5A, transplanted fat
tissue of either localization exhibited a much more inﬂam-
matory gene expression proﬁle than endogenous epididy-
mal fat pads, as assessed by mRNA expression of
proinﬂammatory cytokines and cd11c. Yet intriguingly,
when comparing portal-transplanted to caval-transplanted
fat pads, the former exhibited higher expression levels of
IL-6 and Fas ligand (FasL).
Because IL-6 was previously associated with hepatic
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FIG. 4. A: Left panel: Hematoxylin- and eosin-stained liver sections from sham-operated and pTx mice. Right panel: Total liver lipids were
determined and expressed relative to liver weight. Results represent the mean  SEM of four to six mice of each group. B: mRNA expression of
indicated markers in liver tissue of sham-operated and pTx mice was analyzed. Results are the mean  SEM of ﬁve mice per group, expressed
relative to sham-operated mice and normalized to expression of 18S. C: FFA levels were determined in systemic and portal plasma samples of mice
receiving a portal drained fat transplant (pTx) and in sham-operated mice after3ho ffasting. Results are the mean  SEM of ﬁve to six animals.
TABLE 1
Metabolic characteristics of sham-operated and portal-
transplanted mice
Sham pTx
Before transplantation
Body weight (g) 22.3  0.7 23.0  0.4
Fat pad weight (mg)
Transplant 150  7
At sacriﬁce
Body weight (g) 25.2  0.4 26.0  0.5
Fat pad weight (mg)
Transplant 117  12
Epididymal 215  22 222  29
Mesenteric 135  12 138  11
Retroperitoneal 68  11 59  10
Inguinal 193  21 188  16
Glucose (mmol/l) 5.6  0.7 5.7  0.2
Insulin (pg/ml) 1,295  486 1,479  338
Adiponectin (g/ml) 27.5  3.7 33.0  4.5
Leptin (pg/ml) 66.9  14.6 81.6  23.7
IL-6 (pg/ml) 6.5  0.9 6.8  1.6
FFA (mmol/l) 0.31  0.04 0.39  0.08
Data are means  SE of 5–10 animals. Blood samples were taken 3 h
after fasting.
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expression and secretion from portal-transplanted fat pads
might be responsible for hepatic insulin resistance. Thus,
IL-6 was determined in systemic and portal vein plasma
samples of sham-operated and portal-transplanted mice.
Systemic and portal IL-6 plasma levels were similar in
sham-operated mice, whereas IL-6 concentration was
70% higher in portal than systemic blood samples of
mice receiving a pTx (Fig. 5B). Even though this difference
was not signiﬁcant, these data suggest increased delivery
of IL-6 to the liver of mice receiving a portal transplant,
potentially originating from the transplanted fat pad. Con-
sistent with an increased delivery of IL-6 to the liver,
hepatic SOCS3 mRNA expression, which is induced by
IL-6 (14,15), was enhanced in mice receiving a portal-
transplanted fat pad (Fig. 5C).
To substantiate the potential contribution of IL-6 to the
induction of insulin resistance in portal-transplanted mice,
epididymal fat pads of an IL-6 knockout donor were
transplanted into a wild-type recipient (pTx-IL6KO). Char-
acteristics of these mice are given in supplementary Table
S1. As shown in Fig. 6A, glucose tolerance of such
transplanted mice was not impaired compared with sham-
operated wild-type mice. Moreover, the insulin-induced
increase in Akt phosphorylation in liver samples was
completely maintained in these mice (Fig. 6B) in contrast
to mice receiving a pTx from wild-type mice (Fig. 3C). In
addition, hepatic SOCS-3 mRNA expression was not in-
creased, likely because of IL-6 deﬁciency (Fig. 6C). These
results point toward a causative role for IL-6 in the
development of insulin resistance in portal-transplanted
mice.
DISCUSSION
The “portal hypothesis” proposes that the liver is directly
exposed to FFAs and cytokines increasingly released from
visceral fat tissue into the portal vein of obese subjects,
thus rendering visceral fat accumulation particularly haz-
ardous for the development of hepatic insulin resistance
and type 2 diabetes (2,3). In the present study, we used a
fat transplantation paradigm to (artiﬁcially) increase fat
mass depot speciﬁcally. In accordance with the portal
hypothesis, we demonstrate that fat transplant localization
through its venous drainage determines its effect on glu-
cose homeostasis.
When using a fat pad transplantation paradigm, several
factors need to be taken into account. First, the source of
the transplanted tissue, i.e., which fat depot is used, may
impact the metabolic outcome. Second, the functional
outcome of the transplant may depend on a myriad of host
factors, which include (but are not limited to) the location
(and thus venous drainage) of the transplant. Previous
studies by different groups including our own have exam-
ined the effect of adipose tissue transplantation into the
abdominal cavity (5,6,16). Yet, whereas our group only
used epididymal fat pads for transplantation, the other
groups implemented both subcutaneous and epididymal
fat pads (6,16). In contrast to the study presented here,
Tran et al. (6) observed no changes in glucose tolerance
when epididymal fat pads were transplanted into the
abdominal cavity. However, as discussed by the authors,
fat pads were drained both to the caval as well as to the
portal vein. Similarly, we show here that such dual drain-
age of transplanted fat tissue may in fact result in no net
alteration in glucose tolerance (Fig. 1D). One potential
explanation might be the fact that the beneﬁcial metabolic
effect of the systemically drained fat transplant (5) was
balanced by the detrimental effect of the portal-drained
transplant. On the other hand, the lack of deterioration in
glucose homeostasis of double-transplanted mice or in the
study by Tran et al. might be due to other reasons.
We further used the pTx paradigm to determine poten-
tial mediators of hepatic insulin resistance in conditions
with increased visceral adiposity. Adipose tissue inﬂam-
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FIG. 5. A: Five weeks after transplantation, endogenous epididymal fat pads
(endo), the portal-drained transplant (pTx), and the caval-drained trans-
plant (cTx) were collected and real-time PCR was performed. Results are
the mean  SEM of two to seven animals. **P < 0.01 pTx vs. cTx (ANOVA).
B: IL-6 was measured in systemic and portal plasma samples of mice
receiving a portal-drained fat transplant (pTx) and in sham-operated mice.
Results are the mean  SEM of 8–10 animals. C: Five weeks after transplan-
tation, liver tissue was collected and rtPCR was performed. Results are the
mean  SEM of four to ﬁve animals.
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resistance, and IL-6 was suggested as a potential candidate
(7,13,17). Indeed, IL-6 treatment of hepatocytes induced
insulin resistance in vitro (18), and it seems to be generally
accepted that IL-6 causes hepatic insulin resistance (19).
Particularly, IL-6 was shown to activate the negative
insulin-signaling regulator SOCS3 in C57BL/6J mice
(14,15), resulting in reduced activation of phosphatidylino-
sitol 3-kinase and Akt (18). Furthermore, IL-6 plasma
concentration was 50% greater in the portal vein than in
systemic circulation in obese subjects, and portal vein IL-6
concentration correlated directly with systemic C-reactive
protein concentrations (20). Accordingly, IL-6 expression
in portal-transplanted adipose tissue and IL-6 levels in the
portal vein of such transplanted mice were increased (Fig.
5A and B), whereas portal IL-6 concentration was not
increased in caval-transplanted mice (supplementary Fig-
ure S2). Moreover, hepatic SOCS3 expression was induced
(Fig. 5C) and, consistently, insulin-stimulated Akt-phos-
phorylation was reduced in liver samples of mice receiving
portal transplants (Fig. 3C). Both changes could be pre-
vented in mice receiving transplants from IL-6 knockout
mice (Fig. 6B and C). Interestingly, IL-6 mRNA expression
was also signiﬁcantly increased in caval-transplanted fat
pads compared with endogenous (epididymal) fat pads
(Fig. 5A), consistent with the transplanted fat depot being
the source of the elevated portal IL-6 levels.
Remarkably, fat pads transplanted to both sites were
characterized by increased expression of proinﬂammatory
cytokines (Fig. 5A). Potential explanations might be a
transplant rejection reaction (even though recipient and
donor mice were littermates of inbred colonies) or an
inﬂammatory reaction due to transient transplant hypoxia.
Intriguingly, increased production of proinﬂammatory cy-
tokines by the transplanted fat pads only deteriorated
glucose metabolism when they were drained to the portal
vein. Moreover, mesenteric transplantation of peritoneal
tissue that did not contain adipose tissue had no effect on
glucose tolerance (supplementary Figure S3). These data
suggest that the transplantation procedure on its own does
not deteriorate glucose homeostasis, for example, by
altering the delivery of inﬂammatory mediators from the
gastrointestinal tract. Such a ﬁnding emphasizes the im-
portance of fat tissue localization and thus vascular drain-
age and suggests that the increased production of
proinﬂammatory cytokines as it is found in obesity is
particularly detrimental when released into the portal
circulation supporting the portal hypothesis (3). However,
it needs to be emphasized that we examined an artiﬁcial
system herein, and, even though increased expression of
proinﬂammatory cytokines in adipose tissue of obese
subjects was previously demonstrated (21), the ﬁndings
presented here may not be extrapolated to the situation of
mesenteric fat accumulation. Therefore, we presently can-
not exclude that the impaired glucose tolerance observed
in the portally transplanted mice may not be due to the
additional adipose tissue per se but rather due to the
increased inﬂammatory products related to the transplan-
tation procedure.
Moreover, besides IL-6, other factors may have contrib-
uted to the deterioration of glucose tolerance and hepatic
insulin resistance. Interestingly, lack of IL-6 also reduced
expression of other proinﬂammatory factors such as IL-1
in adipose tissue (supplementary Figure S4). In addition,
reduced cd11c expression levels point toward reduced
macrophage inﬁltration. Rotter et al. (22) suggested that
IL-6 induce insulin resistance in concert with other cyto-
kines that are also upregulated in adipocytes. Especially
IL-6 and IL-1 were shown to mediate the change of
hepatic glucose metabolism, inﬂuencing the glucoregula-
tory action of insulin through their signal pathways involv-
ing protein phosphorylation (21,23). Interestingly, we
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FIG. 6. Both epididymal fat pads were removed from an IL-6 knockout
mouse (donor) and stitched to the mesenterium of a wild-type mouse
(recipient; pTx-IL6KO). A: Intraperitoneal glucose tolerance test (2 g
glucose/kg body wt) was performed 4 weeks after surgical procedure
in mice receiving portal transplants (pTx-IL6KO; ) or in sham-
operated mice (F). B: Insulin (1 U/kg) was injected intraperitoneally
in overnight fasted mice 5 weeks after transplantation. Liver samples
were harvested 15 min later, and phosphorylation of Akt at S473 was
determined by Western blotting. A representative blot is shown in the
upper panel. Results are the mean  SEM of three animals. C: Five
weeks after transplantation, liver tissue was collected and real-time
PCR was performed. Results are the mean  SEM of two to three
animals.
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pads. We previously reported that Fas activation by FasL
treatment induced secretion of IL-6 in 3T3-L1 adipocytes (7).
Conversely, adipocyte-speciﬁc Fas-knockout mice showed
decreased IL-6 expression in adipose tissue and reduced
circulating IL-6 levels (7). Thus, FasL-induced Fas activation
might be responsible for increased IL-6 secretion of portal-
transplanted fat pads, ultimately inducing hepatic insulin
resistance. In support of the latter, FasL expression was not
reduced in portal-transplanted IL-6–deﬁcient fat pads, sug-
gesting that Fas activation may be indeed upstream of IL-6
release (supplementary Figure S4).
Strikingly, hepatic insulin resistance in our model was
not associated with hepatic steatosis (Fig. 4A)o ri n -
creased hepatic Kupffer cell activation (Fig. 4B), since it is
often observed in high-fat diet–induced hepatic insulin
resistance (12). These changes might be due to a direct
effect of high-fat diet on liver metabolism or due to an
increased release of FFAs from (mesenteric) adipose
tissue. Consistent with the latter notion, FFA levels were
found to be increased in high fat–fed mice, which was not
the case in our study.
In conclusion, our results demonstrate that the meta-
bolic fate of intra-abdominal fat tissue transplantation is
determined by the delivery of inﬂammatory cytokines to
the liver speciﬁcally via the portal system providing clear
direct support for the portal hypothesis.
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